Showing 5011-5020 of 8223 results for "".
- FDA: Pills Don't Replace Sunscreenhttps://practicaldermatology.com/news/fda-pills-dont-replace-sunscreen/2457749/The U.S. Food and Drug Administration (FDA) is cracking down on companies marketing supplements that claim to counter the effects of the sun's ultraviolet rays. These companies — marketing products called
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- Dr. Daniel Siegel Joins MedX's Medical Advisory Boardhttps://practicaldermatology.com/news/dr-daniel-siegel-joins-medxs-medical-advisory-board/2457754/Daniel Siegel, MD, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined the Medical Advisory Board of MedX Health Corp. “Daniel’s academic and practical business experience is impres
- New Guidelines May Slightly Increase Reliability, Accuracy of Melanoma Diagnoseshttps://practicaldermatology.com/news/new-guidelines-may-slightly-increase-reliability-accuracy-of-melanoma-diagnoses/2457759/New guidelines may slightly increase reliability and accuracy of melanoma diagnoses, a new study in JAMA Network Open shows. The American Joint Committee on Cancer recently updated its guidelines for melanoma, and the study researchers found that when pathologists used the new gu
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID)
- Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescentshttps://practicaldermatology.com/news/dupixent-improves-moderate-to-severe-atopic-dermatitis-in-adolescents/2457764/DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with DUPIXENT as monotherapy significantly improved measures of overall disease severity, skin c
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato
- National Psoriasis Foundation Honors Dr. Jerry Bagel with Excellence in Leadership Awardhttps://practicaldermatology.com/news/national-psoriasis-foundation-honors-dr-jerry-bagel-with-excellence-in-leadership-award/2457766/Jerry Bagel, MD, an internationally recognized expert in the treatment of psoriasis and founder of Windsor Dermatology and Psoriasis Treatment Center of Central New Jersey, will receive the Excellence in Leadership Award from the National Psoriasis Foundation (NPF) next month. For more th
- Innovations in Skin of Color Dermatology Award Goes to Eliot Battle, MDhttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-goes-to-eliot-battle-md/2457775/Eliot Battle, MD has been awarded the Innovations in Skin of Color Dermatology Award. The award was presented by The&nbs